Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
A Marker of Collagen Type 1 Degradation Reflects Kidney Disease Severity and Fibrosis in IgAN
March 26, 2025
A novel urinary marker of collagen type 1 degradation reflects kidney disease severity and fibrosis in IgA nephropathy.
Introduction
In chronic kidney disease (CKD), kidney fibrosis is characterized by increased collagen deposition and turnover, especially of collagen type I (COL1), the primary protein in the kidney’s extracellular matrix (ECM). Existing techniques for assessing kidney fibrosis are highly invasive and lack sensitivity, highlighting the need for a non-invasive biomarker to identify high-risk patients before irreversible kidney function decline occurA COL1 degradation peptide (231_DDGEAGKPGP) was identified as highly associated with kidney function decline in urine peptidomics studies in CKD patients (3).
The aim of this study was to develop an immunoassay to detect this peptide in urine and evaluate its usefulness in individuals with Immunoglobulin A nephropathy (IgAN).
Poster
Conclusion
We developed a novel and robust urinary assay which showed potential as a non-invasive biomarker of
kidney disease severity and fibrosis in IgAN. It will be of interest to evaluate its prognostic potential in
appropriate kidney disease cohorts and further in other organ diseases to understand the specificity of the biomarker to CKD.
